Objective:

To collate and structure recent findings on the active metabolites and pharmacological effects of Schisandra chinensis Fructus (SCF) in managing metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting its significance in contemporary therapeutic strategies.

Key Findings:

• SCF contains bioactive compounds such as lignans, triterpenoids, volatile oils, and organic acids that protect hepatocytes, reduce hepatic fat, improve insulin sensitivity, and combat oxidative stress, indicating its potential as a therapeutic agent for MASLD.
• The pharmacological effects of SCF's metabolites contribute to the alleviation of MASLD, suggesting a multifaceted approach to treatment.
• A comprehensive investigation into the integrated mechanisms of SCF's metabolites is still needed to fully understand their therapeutic potential.

Interpretation:

The active metabolites of SCF demonstrate significant potential in treating MASLD through various pharmacological mechanisms, warranting further research and development to explore their full impact on therapeutic strategies.

Limitations:

• Insufficient comprehensive studies on the integrated mechanisms of SCF's active metabolites, particularly in diverse populations.
• Limited clinical trials specifically targeting MASLD with SCF, highlighting the need for varied trial designs.

Conclusion:

Understanding the mechanisms of SCF's active metabolites can facilitate further research and application in pharmaceuticals and health foods, supporting drug innovation and functional food development, especially in light of the rising prevalence of MASLD.